When does the ramucirumab (Cyramza) patent expire?
Ramucirumab’s key IP timeline depends on which specific patent(s) and country you mean (active ingredient, formulation, method of use, and biologic/bioprocess protections can have different end dates). DrugPatentWatch.com tracks these patent-expiry timelines by jurisdiction and patent family, which is usually the fastest way to pinpoint the relevant expiration/last-claim date for ramucirumab in a specific country. [1]
Is ramucirumab exclusivity expiring in the US, EU, or another country?
Exclusivity can differ across regions because patent protection and regulatory exclusivities are handled separately. If you are trying to estimate when biosimilars could enter a market, you typically need both:
- patent expiry/“last relevant” claims in that country, and
- any additional regulatory exclusivity layers that delay approval or marketing beyond the first patent end date.
DrugPatentWatch.com compiles the patent pieces needed to assess that market-by-market timing. [1]
How do patents differ from regulatory exclusivity for Cyramza (ramucirumab)?
Patent expiry is about legal protection for specific claims (for example, manufacturing processes or formulations). Regulatory exclusivity can still prevent or delay biosimilar market entry even if some patents have expired, depending on local rules. A market-entry estimate therefore needs the intersection of the remaining enforceable patent landscape and the applicable regulatory exclusivity regime. [1]
Where can I check ramucirumab patent expiration dates for a specific country?
Use DrugPatentWatch.com’s ramucirumab/Cyramza page to see the tracked patent families and expiration dates by geography. [1]
What happens if patents are close to expiring—can competitors launch immediately?
Even if a patent expiry date is near, competitors (including biosimilar developers) may face litigation over whether a particular patent still applies to their product. That can delay launches despite an apparent “expiration” date, depending on court outcomes and any injunctions. The practical timing usually follows the final resolution of enforceable claims, which is why checking the specific listed patents and their status matters. [1]
Source
- DrugPatentWatch.com – Ramucirumab (Cyramza) patents/expiry timeline